Clinical Trial: A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA

U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07738822) titled 'A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA' on July 28.

Brief Summary: A Phase 1b/2a, open-label dose escalation and dose expansion study of subcutaneously (SC) administered velinotamig for the treatment of adults with relapsing and refractory immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) to evaluate safety and tolerability.

Study Start Date: Dec., 2026

Study Type: INTERVENTIONAL

Condition: Immune Thrombocytopenia (ITP) Warm Autoimmune Hemolytic Anemia (WAIHA)

Intervention: DRUG: Velinotamig specified dose on specified days.

Velinotamig is an engineered bisp...